Kyorin Pharmaceutical (TSE: 4569) now guides to an operating loss of ¥4.9bn for the year to March 2027, against a ¥2.0bn profit in its May forecast. Ordinary income moves to a ¥4.6bn loss from a ¥2.3bn profit, and net profit attributable to owners to a ¥5.1bn loss from ¥1.5bn. Sales guidance is untouched at ¥121.8bn.
Two licences, one of them unsigned
The company's revision notice says the operating and ordinary lines absorb two upfront payments. One is for EB05, an ARDS drug candidate licensed from Edesa Biotech, Inc., signed on 9 November. The other covers an in-licensed product that is not yet under contract. Kyorin says it judged the payment highly certain because talks with the counterparty have progressed. The notice names neither the product nor the counterparty, and gives no amount.
For Edesa, Kyorin pays $12mn upfront for exclusive Japanese development and sales rights, up to $134mn in milestones tied to development, price listing and net-sales thresholds, and tiered royalties. It plans to expense the upfront payment in the third quarter. EB05 is in Phase 3 preparation.
The supplementary materials show the full-year R&D forecast at ¥16.2bn, up from ¥9.3bn in the original forecast.
A separate hit to net profit
The net-profit cut is larger than the licensing effect alone. Kyorin booked a ¥2.53bn loss on the transfer of its generics business in the first half: ¥1.93bn of impairment plus advisory costs. The transfer is set for 1 April 2027, and the contract lets Kyorin's costs rise or fall depending on future circumstances. Kyorin's notice says this loss feeds net profit, not the operating and ordinary lines. Earlier Tokyo Brief coverage
First-half sales were ¥57.49bn, down 2.1%, and operating profit was ¥306mn, down 77.6%. The first-half net loss was ¥1.57bn. Kyorin's May forecast had pencilled in an operating loss for the half, so operating profit came in above it as selling and administrative expenses went unspent.
The full-year dividend forecast stays at ¥25 per share.